Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study

INTRODUCTION: The efficacy of iGlarLixi, a fixed-ratio combination of basal insulin glargine 100 units/mL (iGlar) and the short-acting GLP-1 RA lixisenatide (Lixi), was established in people with type 2 diabetes (T2D) who were advancing therapy from oral antidiabetic drugs (OADs) and basal insulin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Đekić, Danijel, Bojić, Mirjana, Janež, Andrej, Klobučar, Sanja, Hadžimušović, Iris Grčić, Ković, Tijana, Mihalevska, Svetla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241758/
https://www.ncbi.nlm.nih.gov/pubmed/37211579
http://dx.doi.org/10.1007/s13300-023-01407-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241758/
https://www.ncbi.nlm.nih.gov/pubmed/37211579
http://dx.doi.org/10.1007/s13300-023-01407-3

Ejemplares similares